Medication in relation to ST-segment elevation myocardial infarction in patients with a first myocardial infarction: Swedish Register of Information and Knowledge about Swedish Heart Intensive Care Admissions (RIKS-HIA)

Archives of Internal Medicine

Volumn 170, Issue 15, 2010, Pages 1375-1381

  Björck, Lena ^a   Wallentin, Lars ^b   Stenestrand, Ulf ^c   Lappas, George ^a   Rosengren, Annika ^a  

^a SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^b UPPSALA CLINICAL RESEARCH CENTER   (Sweden)

^c LINKÖPING UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

ADULT; AGED; ARTICLE; CARDIOVASCULAR RISK; FEMALE; HEART FAILURE; HEART INFARCTION; HOSPITALIZATION; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; ST SEGMENT ELEVATION;

ADRENERGIC BETA-ANTAGONISTS; ADULT; AGED; AGED, 80 AND OVER; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ASPIRIN; CARDIOVASCULAR AGENTS; FEMALE; HEART CONDUCTION SYSTEM; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INTENSIVE CARE UNITS; LOGISTIC MODELS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; MYOCARDIAL INFARCTION; ODDS RATIO; PATIENT ADMISSION; REGISTRIES; SEVERITY OF ILLNESS INDEX; SWEDEN;

EID: 77955451792     PISSN: 00039926     EISSN: 15383679     Source Type: Journal    
DOI: 10.1001/archinternmed.2010.203     Document Type: Article

References (28)

1. Abildstrom SZ, Rasmussen S, Rosen M, Madsen M. Trends in incidence and case fatality rates of acute myocardial infarction in Denmark and Sweden. Heart. 2003;89(5):507-511. (Pubitemid 36520798)
2. McGovern PG, Jacobs DR Jr, Shahar E, et al. Trends in acute coronary heart disease mortality, morbidity, and medical care from 1985 through 1997: the Minnesota heart survey. Circulation. 2001;104(1):19-24.
3. Salomaa V, Miettinen H, Kuulasmaa K, et al. Decline of coronary heart disease mortality in Finland during 1983 to 1992: roles of incidence, recurrence, and case-fatality: the FINMONICA MI Register Study. Circulation. 1996;94(12):3130-3137.
4. Hellermann JP, Reeder GS, Jacobsen SJ, Weston SA, Killian JM, Roger VL. Longitudinal trends in the severity of acute myocardial infarction: a population study in Olmsted County, Minnesota. Am J Epidemiol. 2002;156(3):246-253.
5. Yusuf S, Hawken S, Ounpuu S, et al; INTERHEART Study Investigators. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART Study): case-control study. Lancet. 2004;364(9438):937-952. (Pubitemid 39208455)
6. Björck L, Rosengren A, Bennett K, Lappas G, Capewell S. Modelling the decreasing coronary heart disease mortality in Sweden between 1986 and 2002. Eur Heart J. 2009;30(9):1046-1056.
7. Ford ES, Ajani UA, Croft JB, et al. Explaining the decrease in US deaths from coronary disease, 1980-2000. N Engl J Med. 2007;356(23):2388-2398.
8. Go AS, Iribarren C, Chandra M, et al; Atherosclerotic Disease, Vascular Function and Genetic Epidemiology (ADVANCE) Study. Statin and β-blocker therapy and the initial presentation of coronary heart disease. Ann Intern Med. 2006;144 (4):229-238.
9. Spencer FA, Allegrone J, Goldberg RJ, et al; GRACE Investigators. Association of statin therapy with outcomes of acute coronary syndromes: the GRACE Study. Ann Intern Med. 2004;140(11):857-866.
10. Spencer FA, Santopinto JJ, Gore JM, et al. Impact of aspirin on presentation and hospital outcomes in patients with acute coronary syndromes (the Global Registry of Acute Coronary Events [GRACE]). Am J Cardiol. 2002;90(10):1056-1061.
11. Stenestrand U, Wallentin L; Swedish Register of Cardiac Intensive Care (RIKS-HIA). Early statin treatment following acute myocardial infarction and 1-year survival. JAMA. 2001;285(4):430-436.
12. Alpert JS, Thygesen K, Antman E, Bassand JP. Myocardial infarction redefined: a consensus document of the Joint European Society of Cardiology/American College of Cardiology Committee for the redefinition of myocardial infarction. J Am Coll Cardiol. 2000;36(3):959-969.
13. Davies MJ. The pathophysiology of acute coronary syndromes. Heart. 2000;83(3):361-366.
14. Björck L, Rosengren A, Wallentin L, Stenestrand U. Smoking in relation to STsegment elevation acute myocardial infarction: findings from the Register of Information and Knowledge About Swedish Heart Intensive Care Admissions. Heart. 2009;95(12):1006-1011.
15. Rosengren A, Wallentin L, Simoons M, et al. Cardiovascular risk factors and clinical presentation in acute coronary syndromes. Heart. 2005;91(9):1141-1147. (Pubitemid 41192381)
16. Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ. 2002;324(7329):71-86.
17. Freemantle N, Cleland J, Young P, Mason J, Harrison J. β-Blockade after myocardial infarction: systematic review and meta regression analysis. BMJ. 1999; 318(7200):1730-1737. (Pubitemid 29290470)
18. Gruppo Italiano per lo Studio della Sopravvivenza nell'infarto Miocardico. GISSI-3: effects of lisinopril and transdermal glyceryl trinitrate singly and together on 6-week mortality and ventricular function after acute myocardial infarction. Lancet. 1994;343(8906):1115-1122.
19. ISIS-4 (Fourth International Study of Infarct Survival) Collaborative Group. ISIS-4: a randomised factorial trial assessing early oral captopril, oral mononitrate, and intravenous magnesium sulphate in 58,050 patients with suspected acute myocardial infarction. Lancet. 1995;345(8951):669-685.
20. Lonn EM, Yusuf S, Jha P, et al. Emerging role of angiotensin-converting enzyme inhibitors in cardiac and vascular protection. Circulation. 1994;90(4):2056-2069. (Pubitemid 24320959)
21. Baigent C, Keech A, Kearney PM, et al; Cholesterol Treatment Trialists' (CTT) Collaborators. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet. 2005;366(9493):1267-1278.
22. Mills EJ, Rachlis B, Wu P, Devereaux PJ, Arora P, Perri D. Primary prevention of cardiovascular mortality and events with statin treatments: a network meta-analysis involving more than 65,000 patients. J Am Coll Cardiol. 2008;52(22): 1769-1781.
23. Aronow HD, Topol EJ, Roe MT, et al. Effect of lipid-lowering therapy on early mortality after acute coronary syndromes: an observational study. Lancet. 2001; 357(9262):1063-1068.
24. Schwartz GG, Olsson AG, Ezekowitz MD, et al; Myocardial Ischemia Reduction With Aggressive Cholesterol Lowering (MIRACL) Study Investigators. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL Study: a randomized controlled trial. JAMA. 2001;285(13):1711-1718.
25. Boden WE, O'Rourke RA, Teo KK, et al; COURAGE Trial Research Group. Optimal medical therapy with or without PCI for stable coronary disease. N Engl J Med. 2007;356(15):1503-1516.
26. LaRosa JC. Pleiotropic effects of statins and their clinical significance. Am J Cardiol. 2001;88(3):291-293. (Pubitemid 32721958)
27. Ray KK, Cannon CP. The potential relevance of the multiple lipid-independent (pleiotropic) effects of statins in the management of acute coronary syndromes. J Am Coll Cardiol. 2005;46(8):1425-1433.
28. Myerson M, Coady S, Taylor H, Rosamond WD, Goff DC Jr; ARIC Investigators. Declining severity of myocardial infarction from 1987 to 2002: the Atherosclerosis Risk in Communities (ARIC) Study. Circulation. 2009;119(4):503-514.